Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 4
2018 1
2019 1
2020 2
2021 4
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.
Weppler AM, Da Meda L, Pires da Silva I, Xu W, Grignani G, Menzies AM, Carlino MS, Long GV, Lo SN, Nordman I, Steer CB, Lyle M, Trojaniello C, Ascierto PA, Lebbe C, Sandhu S. Weppler AM, et al. Among authors: da meda l. Eur J Cancer. 2023 Apr;183:109-118. doi: 10.1016/j.ejca.2023.01.016. Epub 2023 Jan 30. Eur J Cancer. 2023. PMID: 36842413
PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.
Delyon J, Biard L, Renaud M, Resche-Rigon M, Le Goff J, Dalle S, Heidelberger V, Da Meda L, Toullec L, Carcelain G, Mourah S, Caillat-Zucman S, Allain V, Battistella M, Lebbe C. Delyon J, et al. Among authors: da meda l. Lancet Oncol. 2022 Apr;23(4):491-500. doi: 10.1016/S1470-2045(22)00097-3. Epub 2022 Mar 10. Lancet Oncol. 2022. PMID: 35279271 Clinical Trial.
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
Yatim N, Boussier J, Tetu P, Smith N, Bruel T, Charbit B, Barnabei L, Corneau A, Da Meda L, Allayous C, Baroudjian B, Jebali M, Herms F, Grzelak L, Staropoli I, Calmettes V, Hadjadj J, Peyrony O, Cassius C, LeGoff J, Kramkimel N, Aractingi S, Fontes M, Blanc C, Rieux-Laucat F, Schwartz O, Terrier B, Duffy D, Lebbé C. Yatim N, et al. Among authors: da meda l. Sci Adv. 2021 Aug 18;7(34):eabg4081. doi: 10.1126/sciadv.abg4081. Print 2021 Aug. Sci Adv. 2021. PMID: 34407944 Free PMC article.
Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans.
Beaziz J, Battistella M, Delyon J, Farges C, Marco O, Pages C, Le Maignan C, Da Meda L, Basset-Seguin N, Resche-Rigon M, Walter Petrich A, Kérob D, Lebbé C, Baroudjian B. Beaziz J, et al. Among authors: da meda l. Cancers (Basel). 2021 May 6;13(9):2224. doi: 10.3390/cancers13092224. Cancers (Basel). 2021. PMID: 34066400 Free PMC article.
Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.
Louveau B, Resche-Rigon M, Lesimple T, Da Meda L, Pracht M, Baroudjian B, Delyon J, Amini-Adle M, Dutriaux C, Reger de Moura C, Sadoux A, Jouenne F, Ghrieb Z, Vilquin P, Bouton D, Tibi A, Huguet S, Rezai K, Battistella M, Mourah S, Lebbe C. Louveau B, et al. Among authors: da meda l. Clin Cancer Res. 2021 Jul 15;27(14):3876-3883. doi: 10.1158/1078-0432.CCR-20-4050. Epub 2021 May 4. Clin Cancer Res. 2021. PMID: 33947696 Clinical Trial.
A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping.
Louveau B, Jouenne F, Têtu P, Sadoux A, Gruber A, Lopes E, Delyon J, Serror K, Marco O, Da Meda L, Ndiaye A, Lermine A, Dumaz N, Battistella M, Baroudjian B, Lebbe C, Mourah S. Louveau B, et al. Among authors: da meda l. Target Oncol. 2020 Dec;15(6):759-771. doi: 10.1007/s11523-020-00764-4. Target Oncol. 2020. PMID: 33151472
17 results